A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age

Highlights • Recombinant inactivated pertussis vaccines are safe in non-pregnant women.• Lower-dose genetically-inactivated pertussis toxin has comparable immunogenicity.• Monovalent recombinant pertussis vaccine shows favorable immunogenicity and safety.

• Publication year

  2021

• Venue

  Vaccine

• Publication date

  2021-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2021.10.076PMID 34789403PMCID 9005647
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines

  2021cited by this paper
• Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.

  2020cited by this paper
• Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review

  2020cited by this paper
• Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.

  2020cited by this paper
• Incidence of Tetanus and Diphtheria in Relation to Adult Vaccination Schedules.

  2020cited by this paper
• Maternal Vaccination in Argentina: Tdap Vaccine Effectiveness During Pregnancy in Preventing Pertussis in Infants Less Than 2 Months of Age.

  2019cited by this paper
• Tetanus vaccines: WHO position paper, February 2017 - Recommendations.

  2018cited by this paper
• Maternal Vaccination With a Monocomponent Pertussis Toxoid Vaccine Is Sufficient to Protect Infants in a Baboon Model of Whooping Cough

  2018cited by this paper
• Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

  2018cited by this paper
• Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update.

  2018cited by this paper
• A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.

  2018cited by this paper
• Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.

  2018cited by this paper
• Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study.

  2018cited by this paper
• Diphtheria vaccine: WHO position paper – August 2017.

  2017cited by this paper
• An update of the global burden of pertussis in children younger than 5 years: a modelling study.

  2017cited by this paper
• Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections.

  2017cited by this paper
• Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation

  2017cited by this paper
• Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction

  2016influential reference
• Assessing the Evidence for Maternal Pertussis Immunization: A Report From the Bill & Melinda Gates Foundation Symposium on Pertussis Infant Disease Burden in Low- and Lower-Middle-Income Countries

  2016influential reference
• Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals

  2016cited by this paper
• Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults

  2016influential reference
• Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination

  2016cited by this paper
• Pertussis vaccines: WHO position paper - September 2015.

  2015cited by this paper
• Pertussis Across the Globe: Recent Epidemiologic Trends From 2000-2013.

  2015cited by this paper
• Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013

  2015cited by this paper
• Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.

  2015cited by this paper
• Effectiveness of maternal pertussis vaccination in England: an observational study.

  2014influential reference
• Immunization policy development in Thailand: the role of the Advisory Committee on Immunization Practice.

  2010cited by this paper
• Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.

  2009cited by this paper
• Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.

  2000cited by this paper
• Physico-chemical analysis of Bordetella pertussis antigens.

  1999cited by this paper
• The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies.

  1996cited by this paper
• A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.

  1996cited by this paper
• EUROPEAN SOCIETY FOR PAEDIATRIC INFECTIOUS DISEASES

  1991cited by this paper

• Glutaraldehyde modifies the catalytic and binding subunits of pertussis toxin, affecting its toxicity and immunogenicity

  2025cites this paper
• Detoxification Techniques for Bacterial Toxins: A Pathway to Effective Toxoid Vaccines.

  2025cites this paper
• Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy

  2025cites this paper
• Humoral and Cellular Immune Response to the Genetically Detoxified S1 Subunit of Pertussis Toxin in Mice

  2025cites this paper
• The Immunogenicity of Glutaraldehyde Inactivated PTx Is Determined by the Quantity of Neutralizing Epitopes

  2025cites this paper
• Infant Responses to Primary Immunization Following Vaccination in Pregnancy With Varying Doses of Recombinant Acellular Pertussis Vaccine Alone or Combined With Tetanus-Diphtheria

  2025cites this paper
• How to improve pertussis vaccination in pregnancy: a European expert review

  2025cites this paper
• Recent development of oral vaccines (Review)

  2024cites this paper
• Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: real-world evidence.

  2024cites this paper
• Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines

  2023cites this paper
• A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women

  2023cites this paper